Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications
- PMID: 28794807
- PMCID: PMC5524249
- DOI: 10.1177/1758834017719215
Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications
Abstract
Advances in our understanding of the mechanisms driving castration-resistant prostate cancer have promoted the development of several new drugs including androgen receptor-directed therapy and chemotherapy. Concomitant docetaxel treatment at the beginning of hormonal therapy for metastatic prostate cancer has resulted in longer overall survival than with hormonal therapy alone. Elucidating an appropriate treatment sequence using these therapies is important for maximizing clinical benefit in castration-sensitive and castration-resistant prostate cancer patients. The development of advanced high-throughput 'omics' technology has enabled the use of novel markers to guide prognosis and treatment of this disease. In this review, we outline the genomic landscape of prostate cancer and the molecular mechanisms of castration-resistant progression, and how these affect the development of new drugs, and their clinical implications for selecting treatment sequence. We also discuss many of the potential tissue-based or liquid biomarkers that may soon enter clinical use, with the hope that several of these prognostic or predictive markers will guide precision medicine for prostate cancer patients in the near future.
Keywords: biomarker; castration-resistant prostate cancer; prostate cancer; treatment.
Conflict of interest statement
Conflict of interest statement: ESA has served as a paid consultant/advisor to Janssen (Raritan, NJ, USA), Johnson & Johnson (New Brunswick, NJ, USA), Medivation (San Francisco, CA, USA) and Astellas (Northbrook, IL, USA); he has also received research funding to his institution from Janssen (Raritan, NJ, USA), Johnson & Johnson (New Brunswick, NJ, USA), Medivation (San Francisco, CA, USA) and Astellas (Northbrook, IL, USA). No other author reports any conflicts of interest.
Similar articles
-
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.Eur Urol. 2019 Jan;75(1):88-99. doi: 10.1016/j.eururo.2018.03.028. Epub 2018 Apr 16. Eur Urol. 2019. PMID: 29673712 Review.
-
Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data.Lancet Oncol. 2017 Jan;18(1):132-142. doi: 10.1016/S1470-2045(16)30560-5. Epub 2016 Nov 16. Lancet Oncol. 2017. PMID: 27864015 Free PMC article. Clinical Trial.
-
Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28. BJU Int. 2012. PMID: 22369348
-
Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies.Cancer. 2015 Feb 1;121(3):361-71. doi: 10.1002/cncr.28929. Epub 2014 Sep 18. Cancer. 2015. PMID: 25236176 Review.
-
Recent advances in the management of metastatic prostate cancer: optimizing use of existing therapies, while searching for novel interventions.Curr Opin Oncol. 2018 May;30(3):159-164. doi: 10.1097/CCO.0000000000000443. Curr Opin Oncol. 2018. PMID: 29553949 Review.
Cited by
-
Multiplexed Prostate Cancer Companion Diagnostic Devices.Sensors (Basel). 2021 Jul 24;21(15):5023. doi: 10.3390/s21155023. Sensors (Basel). 2021. PMID: 34372259 Free PMC article. Review.
-
Clinico-Pathological Factors and AR-LBD Mutations in Early and Late Castration-Resistant Prostate Cancer.Cancer Manag Res. 2024 Oct 21;16:1509-1516. doi: 10.2147/CMAR.S477439. eCollection 2024. Cancer Manag Res. 2024. PMID: 39464307 Free PMC article.
-
An Update on the Prognostic and Predictive Serum Biomarkers in Metastatic Prostate Cancer.Diagnostics (Basel). 2020 Jul 31;10(8):549. doi: 10.3390/diagnostics10080549. Diagnostics (Basel). 2020. PMID: 32752137 Free PMC article. Review.
-
Expression and clinical significance of Caveolin-1 in prostate Cancer after transurethral surgery.BMC Urol. 2018 Nov 13;18(1):102. doi: 10.1186/s12894-018-0418-4. BMC Urol. 2018. PMID: 30424755 Free PMC article.
-
RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.Prostate. 2020 Feb;80(2):133-145. doi: 10.1002/pros.23925. Epub 2019 Nov 15. Prostate. 2020. PMID: 31730277 Free PMC article.
References
-
- Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9–29. - PubMed
-
- Ito K. Prostate cancer in Asian men. Nat Rev Urol 2014; 11: 197–212. - PubMed
-
- Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502–1512. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources